The Commissioner is authorized to charge any additional fees, including any extension fees, or other relief, as may be required, or credit any overpayment to Deposit Account No. 06-1300 (Our Order No. A-63915/RMS/AMS). Prior to examination, please amend the above-identified application as follows:

In the Claims:

Please cancel claims 44-57, without prejudice or disclaimer.

Please add the following new claims:

58. A method of screening a plurality of cells, comprising:

a) producing a plurality of cells comprising a library of nucleic acids encoding a library of exogenous scaffolds;

b) introducing into said plurality of cells a library of nucleic acids each encoding at least a first enzyme and a second enzyme; and

c) screening said plurality of cells for a cell comprising at least one exogenous scaffold and exhibiting an altered phenotype,

wherein each of said scaffolds comprises at least a first binding site and a second binding site, and wherein said first enzyme binds to said first binding site and said second enzyme binds to said second binding site.

59. The method of claim 58, further comprising contacting said cells, prior to said screening, with a library of exogenous bioactive agent precursors.

60. A method according to claim 58, wherein each said scaffold comprises at least three binding sites.

61. A method according to claim 58, wherein each said scaffold comprises at least four binding sites.

62. A method according to claim 58, wherein each said scaffold comprises at least five binding sites.

63. A method according to claim 58, wherein said cells are mammalian cells.

64. A method according to claim 58, wherein said scaffolds are linear.

65. A method according to claim 58, wherein said library of nucleic acids encoding a library of exogenous scaffolds further comprises at least one targeting sequence.

66. A method according to claim 58, wherein said library of nucleic acids encoding a library of exogenous scaffolds further comprises at least one rescue sequence.

67. A method according to claim 58, wherein said library of nucleic acids encoding a library of exogenous scaffolds further comprises at least one stability sequence.

68. A method according to claim 58, wherein said library of nucleic acids encoding at least a first enzyme and a second enzyme further comprises at least one targeting sequence.

69. A method according to claim 58, wherein said library of nucleic acids encoding at least a first enzyme and a second enzyme further comprises at least one rescue sequence.

70. A method according to claim 58, wherein said library of nucleic acids encoding at least a first enzyme and a second enzyme further comprises at least one stability sequence.

71. A method according to claim 58, wherein said introducing comprises retroviral infection.

72. A method according to claim 58, wherein said method further comprises isolating said cell exhibiting an altered phenotype.

73. A method according to claim 58 further comprising isolating said scaffold from said cell exhibiting an altered phenotype.

74. A method according to claim 58 further comprising isolating said nucleic acid encoding said scaffold from said cell exhibiting an altered phenotype.

75. A method according to claim 58 further comprising isolating said enzymes from said cell exhibiting an altered phenotype.

76. A method according to claim 58 further comprising isolating said nucleic acids encoding said enzymes from said cell exhibiting an altered phenotype.

77. A method according to claim 59, wherein said altered phenotype is due to the presence of one or more of said bioactive agent precursors.

78. A method according to claim 77 further comprising identifying said one or more bioactive agents.